| __timestamp | Alnylam Pharmaceuticals, Inc. | Apellis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 2908166 |
| Thursday, January 1, 2015 | 60610000 | 6356782 |
| Friday, January 1, 2016 | 89354000 | 4303743 |
| Sunday, January 1, 2017 | 199365000 | 10463151 |
| Monday, January 1, 2018 | 382359000 | 22639184 |
| Tuesday, January 1, 2019 | 479005000 | 67046483 |
| Wednesday, January 1, 2020 | 588420000 | 139401000 |
| Friday, January 1, 2021 | 620639000 | 176771000 |
| Saturday, January 1, 2022 | 770658000 | 277163000 |
| Sunday, January 1, 2023 | 795646000 | 500815000 |
| Monday, January 1, 2024 | 975526000 |
Cracking the code
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Alnylam Pharmaceuticals and Apellis Pharmaceuticals, two giants in the field, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting their aggressive expansion and market penetration strategies. In contrast, Apellis, while also experiencing a significant increase, saw a more moderate rise of around 17,000% in the same period. This disparity highlights Alnylam's consistent investment in administrative and sales functions, while Apellis has shown a more recent acceleration in spending, particularly noticeable in the last two years. As these companies continue to innovate, their financial strategies will play a pivotal role in shaping their future trajectories.
Sanofi or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Gilead Sciences, Inc. vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: argenx SE vs Apellis Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Incyte Corporation
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or PTC Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?